Phase I/II Study of Gleevec (Imatinib Mesylate, Formerly Known as STI571) and Gemcitabine for Advanced Pancreas Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 25 Aug 2011
At a glance
- Drugs Gemcitabine (Primary) ; Imatinib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 25 May 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 23 Aug 2006 New trial record.